The FDA is in a public comment period - closing June 29, 2026 - on a proposal to formally exclude semaglutide and tirzepatide from the 503B Bulk Drug Substances List, a move that would permanently close large-scale compounding pathways for these active ingredients even in a future shortage
The most common reason side effects are severe is that the dose needs adjustment, not that the medication isnt right for you. Dr
CJC-1295 and Ipamorelin are commonly researched together for their effects on natural growth hormone release
We start with a thorough evaluation to ensure youre a good candidate, and then provide ongoing monitoring and support tailored to your needs
The BODi community empowers millions to stay motivated and accountable, supporting healthy weight management, improved metabolic function, increased mental and physical well-being, better sleep, as well as evidence-based habits that enhance healthspan and longevity
Originally published on the WashU Medicine website